iifl-logo

Lupin Ltd Share Price

2,005
(2.54%)
Apr 2, 2025|12:59:59 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open1,959.25
  • Day's High2,013.35
  • 52 Wk High2,402.9
  • Prev. Close1,955.4
  • Day's Low1,938.55
  • 52 Wk Low 1,493.3
  • Turnover (lac)13,364.98
  • P/E28.55
  • Face Value2
  • Book Value510
  • EPS68.52
  • Mkt. Cap (Cr.)91,541.29
  • Div. Yield0.41
View All Historical Data
Loading...
  • Open1,812.9
  • Day's High1,823.4
  • Spot1,798
  • Prev. Close1,817
  • Day's Low1,799.45
  • ViewShort BuildUp
  • Market Lot425
  • OI(Chg %)10,57,825 (29.8%)
  • Roll Over%1.66
  • Roll Cost0.83
  • Traded Vol.44,75,675 (21.97%)
View More Futures

Lupin Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

1,959.25

Prev. Close

1,955.4

Turnover(Lac.)

13,364.98

Day's High

2,013.35

Day's Low

1,938.55

52 Week's High

2,402.9

52 Week's Low

1,493.3

Book Value

510

Face Value

2

Mkt Cap (₹ Cr.)

91,541.29

P/E

28.55

EPS

68.52

Divi. Yield

0.41

Lupin Ltd Corporate Action

31 Mar 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

6 May 2024

12:00 AM

Dividend

Dividend Amount: 8

Record Date: 16 Jul, 2024

arrow

9 Jul 2024

12:00 AM

AGM

Announcement Date: 09 Jul, 2024

arrow

Lupin Ltd NEWS AND UPDATE

Lupin Expands US Portfolio with USFDA Approval for Amifampridine
17 Mar 2025|10:28 PM

Lupin said the tablets would be made at its Goa facility, which would bolster its global manufacturing capabilities and continued dedication to delivering affordable medications.

Read More
Top Stocks for Today - 10th March 2025
10 Mar 2025|07:25 AM

Here are some of the stocks that may see significant price movement today: IREDA, Gensol Engineering, Tata Power, etc.

Read More
Lupin’s Somerset Facility Receives USFDA EIR
24 Feb 2025|09:19 AM

The inspection covered the period from January 27 until January 31, 2025, and was used to assess cGMP and other regulatory requirements at the facility

Read More
Top Stocks for Today - 24th February 2025
24 Feb 2025|07:10 AM

Here are some of the stocks that may see significant price movement today: Bharti Airtel, Vedanta, Rail Vikas Nigam (RVNL), etc.

Read More
Lupin Secures USFDA Nod for Generic Atrovent Nasal Spray
11 Feb 2025|11:31 PM

Ipratropium Bromide Nasal Solution (0.03%) is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Lupin Ltd SHAREHOLDING SNAPSHOT

02 Apr, 2025|01:19 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 0.28%

Foreign: 0.28%

Indian: 46.66%

Non-Promoter- 46.79%

Institutions: 46.78%

Non-Institutions: 6.26%

Custodian: 0.00%

Share Price

Lupin Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

91.22

91

90.9

90.79

Preference Capital

0

0

0

0

Reserves

20,511.87

18,320.86

18,059.29

18,474.78

Net Worth

20,603.09

18,411.86

18,150.19

18,565.57

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

11,771.67

11,055.93

11,025.66

10,080.58

yoy growth (%)

6.47

0.27

9.37

-20.16

Raw materials

-4,467.26

-4,182.31

-4,207.27

-3,474.35

As % of sales

37.94

37.82

38.15

34.46

Employee costs

-1,918.16

-1,695.86

-1,703.22

-1,441.64

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

-161.53

1,629.7

1,811.46

1,793.93

Depreciation

-514.19

-502.83

-518.75

-389.81

Tax paid

-27.17

-371.08

-324.7

-449.27

Working capital

-135.75

-894.67

-203.16

1,003.92

Other operating items

View Cash Flow
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

6.47

0.27

9.37

-20.16

Op profit growth

-89.76

7.15

-8.54

-53.5

EBIT growth

-105.27

-10.39

2.01

-56.58

Net profit growth

-114.99

72.99

-45.89

-57.19

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

19,656.34

16,269.98

16,192.79

14,926.99

15,142.8

Excise Duty

0

0

0

0

0

Net Sales

19,656.34

16,269.98

16,192.79

14,926.99

15,142.8

Other Operating Income

354.48

371.68

212.69

235.97

231.96

Other Income

120.17

73.36

142.05

137.62

617.8

Lupin Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,698.35

129.244,07,155.151,181.050.85,985.3398.33

Divis Laboratories Ltd

DIVISLAB

5,549.7

71.051,47,295.245940.542,297513.62

Cipla Ltd

CIPLA

1,444.25

25.071,16,664.331,438.150.94,134.87360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,183.9

59.031,07,673.274850.882,330222.38

Mankind Pharma Ltd

MANKIND

2,458.1

52.421,01,358.17416.3802,396.57334.17

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Lupin Ltd

Management

Register Office

Registrar Office

Chairman (Non-Executive)

M D Gupta

Managing Director

Nilesh Deshbandhu Gupta.

Director & Chief Executive Off

Vinita Gupta

Company Sec. & Compli. Officer

R V Satam

Independent Director

Jean-Luc Belingard

Executive Director & CFO

Ramesh Swaminathan

Independent Director

Mark D McDade

Independent Director

K B S Anand

Independent Director

Punita Kumar Sinha

Independent Director

Jeffrey Kindler

Independent Director

Alfonso Zulueta

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments.Lupin Ltd was incorporated in the year 1983 with the name Lupin Chemicals Ltd. In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar. In the year 1989, the company established a joint venture in Thailand, namely Lupin Chemicals (Thailand) Ltd. In the year 1991, they initiated production of Injectable cephalosporin (bulk and dosages) at Mandideep. In the year 1992, the company set up Fermentation Plant at Tarapur, Maharashtra. Also, Sterile Plant for injectable Cephalosporins (bulk) was commissioned at Mandideep.In the year 2001, Lupin Laboratories Ltd was amalgamated with the company and the name was changed to Lupin Ltd. They commenced supply of Cephalosporin bulk actives to their alliance partners in the US. Also, they commissioned a state of the art US FDA approvable oral cephalosporin bulk active plant. In the year 2002, the company commissioned the new Anti-TB facility at Aurangabad. In the year 2003, the
Read More

Company FAQs

What is the Lupin Ltd share price today?

The Lupin Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹2005 today.

What is the Market Cap of Lupin Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lupin Ltd is ₹91541.29 Cr. as of 02 Apr ‘25

What is the PE and PB ratio of Lupin Ltd?

The PE and PB ratios of Lupin Ltd is 28.55 and 4.06 as of 02 Apr ‘25

What is the 52 Week High and Low of Lupin Ltd?

The 52-week high/low is the highest and lowest price at which a Lupin Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Lupin Ltd is ₹1493.3 and ₹2402.9 as of 02 Apr ‘25

What is the CAGR of Lupin Ltd?

Lupin Ltd's CAGR for 5 Years at 27.56%, 3 Years at 36.70%, 1 Year at 20.42%, 6 Month at -10.89%, 3 Month at -17.32% and 1 Month at 0.13%.

What is the shareholding pattern of Lupin Ltd?

The shareholding pattern of Lupin Ltd is as follows:
Promoters - 46.95 %
Institutions - 46.79 %
Public - 6.26 %

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.